Dolutegravir and Rilpivirine
- Generic Name
- Dolutegravir and Rilpivirine
- Indication
用于治疗接受稳定的抗逆转录病毒治疗方案达到病毒学抑制（HIV-1 RNA小于50拷贝/mL）至少六个月，无病毒学失败史，且对非核苷类逆转录酶抑制剂或整合酶抑制剂没有已知或疑似耐药性的成人人类免疫缺陷病毒1型（HIV-1）感染患者。
GSK Acquires Efimosfermin for $1.2 Billion to Target Steatotic Liver Disease
• GSK has agreed to acquire efimosfermin alfa from Boston Pharmaceuticals for $1.2 billion upfront, with potential additional milestone payments of $800 million, strengthening its hepatology pipeline.
• Efimosfermin, a phase III-ready FGF21 analog, has shown promising results in reversing liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH), with a convenient once-monthly dosing regimen.
• Steatotic liver disease affects approximately 5% of the global population with limited treatment options, and interventions that reduce fibrosis could save the US healthcare system between $40-100 billion over the next two decades.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath